Elspeth Morrison Beauchamp

Personal profile

Research Interests

Dr. Beauchamp's research has focused on developing drugs for non-traditional targets through inhibiting protein-protein interactions in order to affect cellular function and target cancer cells. Current work is investigating novel interactors with mTORC components in order to developing novel therapeutic strategies that target the mTOR pathways in myeloid leukemias.

Education/Academic qualification

PhD, Georgetown University

… → 2010

Research interests

Biochemistry: Proteins
Blood Cancer (leukemia and lymphomas)
Cancer Biology
Drug Discovery
Signal Transduction

Fingerprint Dive into the research topics where Elspeth Morrison Beauchamp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

11 Similar Profiles

Acute Myeloid Leukemia Medicine & Life Sciences

Medulloblastoma Medicine & Life Sciences

Ewing's Sarcoma Medicine & Life Sciences

Phosphotransferases Medicine & Life Sciences

Sirolimus Medicine & Life Sciences

Phosphatidylinositol 3-Kinases Medicine & Life Sciences

Antineoplastic Agents Medicine & Life Sciences

Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2024

1 Active
2 Finished

Targeting Novel Protein Complexes for the Treatment of Acute Myeloid Leukemia

Altman, J. K., Beauchamp, E. M., Eklund, E. A. & Platanias, L. C.

National Cancer Institute

6/1/19 → 5/31/24

Project: Research project

Cyclin-Dependent Kinase 9

Protein Transport

Acute Myeloid Leukemia

Protein Biosynthesis

Heterografts

VA IPA for Elspeth Beauchamp

Beauchamp, E. M. & Platanias, L. C.

Jesse Brown VA Medical Center

10/1/15 → 7/31/19

Project: Research project

Job Description

Immunoblotting

Transfection

Molecular Biology

Phosphotransferases

Elspeth Beauchamp IPA

Beauchamp, E. M. & Platanias, L. C.

Jesse Brown VA Medical Center

11/1/13 → 9/30/16

Project: Research project

Research Output 2008 2019

914 Citations
22 Article
2 Comment/debate
1 Review article

Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening

Mishra, R. K., Clutter, M. R., Blyth, G. T., Kosciuczuk, E. M., Blackburn, A. Z., Beauchamp, E. M., Schiltz, G. E. & Platanias, L. C., Oct 1 2019, In : Chemical Biology and Drug Design. 94, 4, p. 1813-1823 11 p.

Research output: Contribution to journal › Article

Screening

Phosphotransferases

Throughput

Acute Myeloid Leukemia

Mutation

4 Citations (Scopus)

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

Beauchamp, E. M., Abedin, S. M., Radecki, S. G., Fischietti, M., Arslan, A. DI., Blyth, G. T., Yang, A., Lantz, C., Nelson, A., Goo, Y. A., Akpan, I., Eklund, E. A., Frankfurt, O., Fish, E. N., Thomas, P. M., Altman, J. K. & Platanias, L. C., Jan 1 2019, In : Blood. 133, 11, p. 1171-1185 15 p.

Research output: Contribution to journal › Article

Cyclin-Dependent Kinase 9

Sirolimus

Acute Myeloid Leukemia

Cytoplasm

Chemical activation

Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma

Eckerdt, F., Clymer, J., Bell, J. B., Beauchamp, E. M., Blyth, G. T., Goldman, S. & Platanias, L. C., Dec 1 2019, In : Scientific reports. 9, 1, 12822.

Research output: Contribution to journal › Article

Open Access

Medulloblastoma

Phosphatidylinositol 3-Kinases

Antineoplastic Agents

Pharmacology

Neoplastic Stem Cells

1 Citation (Scopus)

Potent antineoplastic effects of combined PI3Kα-MNK inhibition in medulloblastoma

Eckerdt, F. D., Bell, J. B., Beauchamp, E. M., Clymer, J., Blyth, G. T., Kosciuczuk, E. M., Ma, Q., Chen, D. Z., Horbinski, C. M., Goldman, S., Munshi, H. G., Hashizume, R. & Platanias, L. C., Jun 1 2019, In : Molecular Cancer Research. 17, 6, p. 1305-1315 11 p.

Research output: Contribution to journal › Article

Medulloblastoma

Mitogen-Activated Protein Kinase Kinases

Phosphatidylinositol 3-Kinases

Antineoplastic Agents

Neoplastic Stem Cells

8 Citations (Scopus)

Differential response of glioma stem cells to arsenic trioxide therapy is regulated by MNK1 and mRNA translation

Bell, J. B., Eckerdt, F., Dhruv, H. D., Finlay, D., Peng, S., Kim, S., Kroczynska, B., Beauchamp, E. M., Alley, K., Clymer, J., Goldman, S., Cheng, S. Y., James, C. D., Nakano, I., Horbinski, C., Mazar, A. P., Vuori, K., Kumthekar, P., Raizer, J., Berens, M. E. & 1 others, Platanias, L. C., Jan 2018, In : Molecular Cancer Research. 16, 1, p. 32-46 15 p.

Research output: Contribution to journal › Article

MAP Kinase Kinase 1

Protein Biosynthesis

Glioma

Stem Cells

Glioblastoma